Effect of CpG ODN on monocytic myeloid derived suppressor cells

被引：22

作者：

Shirota, Hidekazu ^{[1
,2
]}

Klinman, Dennis M. ^{[1
]}

机构：

[1] NCI, Canc & Inflammat Program, Frederick, MD 21701 USA

[2] SAIC Frederick Inc, Basic Sci Program, Frederick, MD USA

来源：

ONCOIMMUNOLOGY | 2012年 / 1卷 / 05期

关键词：

myeloid-derived suppressor cells; tumor-associated macrophages; CpG ODN; toll like receptor; immunotherapy; tumor microenvironment; myeloid derived suppressor cells; CpG oligonucleotides; TLR9; PF-3512676; CARCINOMA; CANCER;

D O I：

10.4161/onci.19731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CpG oligonucleotides stimulate via TLR9 and enhance anti-tumor immunity, an effect attributed to the activation of NK and CD8+ T cells. Our recent work demonstrates that CpG ODN also induce monocytic myeloid-derived suppressor cells to mature into M1 macrophages, further aiding tumor elimination. This provides insight into the mechanism through which CpG promote tumor regression.

引用

页码：780 / 782

页数：3

共 11 条

[1] Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm [J].

Biswas, Subhra K. ;

Mantovani, Alberto .

NATURE IMMUNOLOGY, 2010, 11 (10) :889-896

[2] In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study [J].

Brody, Joshua D. ;

Ai, Weiyun Z. ;

Czerwinski, Debra K. ;

Torchia, James A. ;

Levy, Mia ;

Advani, Ranjana H. ;

Kim, Youn H. ;

Hoppe, Richard T. ;

Knox, Susan J. ;

Shin, Lewis K. ;

Wapnir, Irene ;

Tibshirani, Robert J. ;

Levy, Ronald .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4324-4332

[3] Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model [J].

Heckelsmiller, K ;

Rall, K ;

Beck, S ;

Schlamp, A ;

Seiderer, J ;

Jahrsdörfer, B ;

Krug, A ;

Rothenfusser, S ;

Endres, S ;

Hartmann, G .

JOURNAL OF IMMUNOLOGY, 2002, 169 (07) :3892-3899

[4] Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma [J].

Hofmann, Maja A. ;

Kors, Christian ;

Audring, Heike ;

Walden, Peter ;

Sterry, Wolfram ;

Trefzer, Uwe .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (05) :520-527

[5] The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors [J].

Kawai, Taro ;

Akira, Shizuo .

NATURE IMMUNOLOGY, 2010, 11 (05) :373-384

[6] Immunotherapeutic uses of CpG oligodeoxynucleotides [J].

Klinman, DM .

NATURE REVIEWS IMMUNOLOGY, 2004, 4 (04) :248-257

[7] Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients [J].

Molenkamp, Barbara G. ;

Sluijter, Berbel J. R. ;

van Leuwen, Paul A. M. ;

Santegoets, Saskia J. A. M. ;

Meijer, Sybren ;

Wijnands, Pepijn G. J. T. B. ;

Haanen, John B. A. G. ;

van den Eertwegh, Alfons J. M. ;

Scheper, Rik J. ;

de Gruijl, Tanja D. .

CLINICAL CANCER RESEARCH, 2008, 14 (14) :4532-4542

[8] Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer [J].

Ostrand-Rosenberg, Suzanne ;

Sinha, Pratima .

JOURNAL OF IMMUNOLOGY, 2009, 182 (08) :4499-4506

[9] Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells [J].

Shirota, Yuko ;

Shirota, Hidekazu ;

Klinman, Dennis M. .

JOURNAL OF IMMUNOLOGY, 2012, 188 (04) :1592-1599

[10] Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists [J].

Vollmer, Joerg ;

Krieg, Arthur M. .

ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (03) :195-204

← 1 2 →